Paraneoplastic pemphigus associated with Castleman's disease
Journal of Paediatrics and Child Health · 2023-03 · 59 (3) · 573-576
DOI: 10.1111/jpc.16361 ↗At a glance
Fallbericht in Journal of Paediatrics and Child Health, published online on 2023-01-30. Written by Maria Relvas and 6 co-authors. Institution: Dermatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal. Major MEDLINE topics: Pemphigus, Castleman Disease. Cited 4 times so far (Crossref); 16 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
A 15-year-old male, with personal history of limb-girdle muscular dystrophy, was admitted to the paediatric ward for a 1-month history of pruritic, generalised, polymorphous eruption and severe painful mucositis. Two months earlier he had been diagnosed with SARS-CoV-2-induced mucositis and treated with prednisolone 40 mg/day for 2 weeks with improvement. At home, due to further therapeutic non-compliance by the patient, mucous lesions recurred associated with a de novo skin eruption, leading him to the emergency department and subsequent hospitalisation. Physical examination revealed shiny, erythematous, flat-toped papules, scarce tense blisters and erosions, scattered over the trunk and extremities, sparing the face. There were multiple palmoplantar blisters and peri-ungual erythema, erosions and crusts. There were widespread erosions of the oral mucosa extending to the vermillion, where there were also pseudomembranes and haemorrhagic crusts (Fig. 1). The glans penis and conjunctiva showed erosions and hyperaemia, respectively. Nikolsky sign was negative. Neither lymphadenopathy nor organomegaly was noticed. Biopsy of a blister demonstrated foci of acantholysis in the mid and superficial epidermis and vacuolization of the basal layer with few apoptotic keratinocytes (Fig. 2). In the superficial dermis, there was moderate perivascular lymphocytic infiltrate. Direct immunofluorescence of perilesional skin revealed intercellular deposition of immunoglobulin G (IgG) and C3. Immunoprecipitation showed anti-desmoglein-3 and anti-desmoglein-1 antibodies. Clinical, histological and immunofluorescence findings established the diagnosis of paraneoplastic pemphigus (PNP). The patient started methylprednisolone 80 mg/day (1 mg/kg/day). Further investigation, including complete blood count, renal and liver functions, protein electrophoresis and anti-nuclear antibodies, was unremarkable. Normal serologies for herpes simplex virus and Mycoplasma pneumoniae, ruled out other possible causes of mucositis. Positron emission tomography/computed tomography (PET/CT) showed multiple retroperitoneal lymphadenopathies and a 62 × 105 × 118 mm hypermetabolic, lobulated mass (Fig. 3), of which biopsies were inconclusive, exhibiting inflammatory infiltrate alone. During this time, due to lack of improvement with corticosteroid therapy alone, azathioprine 50 mg/day was added and an eight-session treatment with plasmapheresis was performed. Following this, the patient underwent incomplete resection of the tumour, whose histologic examination revealed a hyaline vascular variant of Castleman's disease. Given the involvement of multiple lymph nodes, the patient was diagnosed with multicentric Castleman's disease. Considerable improvement over the first month following surgery allowed a reduction of methylprednisolone to 16 mg/day. Since a second procedure to remove the remaining tumour was not feasible, and the patient still had few painful skin lesions with significant mucositis, he started monthly cycles of intravenous immunoglobulin (IVIg) 1 g/kg. During the next 6 months, he showed global improvement of the dermatosis (Fig. 4), despite maintaining refractory oral mucositis. Currently, he is being treated with methylprednisolone 16 mg/day, azathioprine 100 mg/day and monthly IVIg, showing stable disease, but recurrent infectious complications requiring hospitalisation and multiple antibiotic regimens. He has now completed 10 months of follow-up. PNP is a multisystemic autoimmune disease characterised by: painful mucositis refractory to therapy; polymorphic skin lesions (lichenoid, targetoid, blistering, erosive or confluent erythema); acantholysis and lichenoid or interface dermatitis on histological examination; and immunoprecipitation of various proteins, namely envoplakin, periplakin, plectin, desmoglein-1 and desmoglein-3.1, 2 Direct immunofluorescence of the perilesional skin demonstrates intercellular deposition of IgG and C3, and additional staining along the dermal-epidermal junction.3 As the name implies, it occurs in the context of neoplasms, usually of lymphoproliferative origin, including chronic lymphocytic leukaemia and non-Hodgkin lymphoma, and less frequently thymoma, sarcomas and carcinomas.4, 5 PNP is an uncommon condition in paediatric patients, with few case reports and small case series described in literature, representing a diagnostic challenge. Due to the oral blistering and polymorphic skin eruption, differential diagnoses include herpes simplex virus infection, Mycoplasma pneumonia-induced rash and mucositis, reactive infectious mucocutaneous eruption, erythema multiforme major, Stevens-Johnson syndrome/toxic epidermal necrolysis, lichen planus or other autoimmune blistering diseases.6 In fact, our patient had initially been diagnosed with a SARS-CoV-2-induced mucositis at another clinic, which may have represented the initial stage of PNP. Most reported cases in children are associated with Castleman's disease.2, 3, 6-8 Other less frequently reported neoplasms in this age group include T-cell lymphoblastic lymphoma,9 follicular dendritic cell sarcoma10 and myofibroblastic tumour.11 Castleman's disease is a rare, non-clonal neoplasm of lymphatic origin, most commonly developing in the retroperitoneal space, namely the renal fossa or the base of the bladder, and the chest.1 Clinically, it can be classified as unicentric or multicentric, according to the involvement of lymph nodes (multicentric if two or more lymph nodes or regions involved). There are three recognised pathological variants: hyaline vascular, plasma-cell and mixed cellular.1 The tumour may be present for several months before autoimmunity develops. The underlying mechanisms are not completely understood, but the autoimmune phenomenon may result from tumoral deregulated cytokine production, especially interleukin-6, and/or an attack against plakin antigens, presented by dendritic follicular cells of the tumour.1 A high index of suspicion is necessary to diagnose Castleman's disease, not only for its rarity but also because it can have benign histological features on biopsy, not demonstrating clonality.7 In the setting of a suspected PNP, if a tumour is not readily detectable, continued surveillance is indicated. PNP is associated with respiratory disease, more specifically bronchiolitis obliterans. This may be related to the expression of plakin proteins in the respiratory epithelium, which are recognised by PNP antibodies. In fact, IgG has been shown to be deposited on the affected bronchial epithelium.12 Respiratory involvement usually predicts a complicated course of the disease and bronchiolitis obliterans may be the leading cause of mortality in children with PNP associated with Castleman's disease.13 A relationship between PNP and myasthenia gravis has also been reported, especially in patients with associated thymoma or Castleman's disease, although there are no studies restricted to paediatric population.14, 15 In contrast to bronchiolitis obliterans, myasthenia gravis does not seem to change the overall survival in these patients.15 Generally, PNP has a poor prognosis and a progressive course, regardless of the patient's age.7 When associated with Castleman's disease, the 3-year survival rate is less than 60%.14 Whether prognosis differs between unicentric and multicentric disease is uncertain.6 The eradication of the underlying tumour may have some benefit in the mucocutaneous lesions; nonetheless, even after complete resection, the autoimmune process may remain active for many years.16 Moreover, there are reports where the pulmonary involvement not only persisted but progressed after tumour resection.13, 14 Systemic therapy with thalidomide, lenalidomide, bortezomib, cytotoxic chemotherapy, rituximab or siltuximab (anti-interleukin-6 monoclonal antibody) may be considered for treatment of residual disease.6, 14 Post-operative adjunctive immunosuppression is, therefore, necessary for long periods of time and diverse agents have been used, despite their low efficacy.3 These include oral corticosteroids, cyclosporin, cyclophosphamide, azathioprine, mycophenolate mofetil, rituximab, IVIg, plasmapheresis and immunopheresis.3, 14 Data regarding the efficacy of these agents in paediatric population are lacking, in part due to the short follow-up periods resulting from elevated mortality. In our patient, IVIg plus azathioprine and low-dose methylprednisolone showed some benefit, with improvement of the cutaneous eruption, but persistence of relapsing oral mucositis. This is in line with the results found in a case series of PNP associated with Castleman's disease,1 showing that patients with unresectable disease may transiently benefit from combined regimens, despite the inevitability of symptomatic recurrence. Besides, the follow-up period of our patient is still very short. The diagnosis of PNP in paediatric population may not be easy, mainly for its rarity. The recognition of the characteristic polymorphic skin eruption, alongside its histological features and immunoprecipitation profile, is important since it can represent the first sign of a haematological or visceral malignancy. When PNP is diagnosed in children, Castleman's disease must always be considered. The authors would like to thank Dr Nelson Neves, Dr Paula Estanqueiro, Dr Manuel Salgado and Dr João Nascimento (Department of Pediatrics, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal) for their essential support in the management of the patient.
Subjects
MeSH terms (MEDLINE)
Authors and institutions
- Dermatology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- Department of Pediatrics, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
- Dermatology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal.
ORCID profiles: Maria Relvas
Cite
APA
Relvas, M., Xará, J., Lucas, M., Coelho, S., Coutinho, I., Cardoso, J. C., & Ramos, L. (2023). Paraneoplastic pemphigus associated with Castleman's disease. Journal of Paediatrics and Child Health, 59(3), 573-576. https://doi.org/10.1111/jpc.16361
Vancouver
Relvas M, Xará J, Lucas M, Coelho S, Coutinho I, Cardoso JC, et al. Paraneoplastic pemphigus associated with Castleman's disease. Journal of Paediatrics and Child Health. 2023;59(3):573-576. doi:10.1111/jpc.16361
BibTeX
@article{Relvas2023,
author = {Relvas, Maria and Xará, Joana and Lucas, Miguel and Coelho, Sónia and Coutinho, Inês and Cardoso, José C and Ramos, Leonor},
title = {Paraneoplastic pemphigus associated with Castleman's disease},
journal = {Journal of Paediatrics and Child Health},
year = {2023},
volume = {59},
number = {3},
pages = {573--576},
doi = {10.1111/jpc.16361}
}
EUVIMED